Replies to post #592 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

...and that's whats "unfortunate" about the situation.

Deforolimus/Ridaforolimus, at the time, did not have a valid targeted agent to use in combination.

Recent data in broad medical publications clearly have said that combining mTORs with other agents targeting pathways in the PI3 Kinase are more likely to show higher levels of efficacy due to their interaction with feedback loops which make the drug (in this case RIDA) less effective and prone to causing the cancer to grow (e.g., the cancer evolves and finds a way around the inhibitor - but you already know this).

mTORs will be MUCH more likely to succeed in combination, and I think DALO (IGF1R) is a great combination and has been spoken about quite frequently in medical journals (regarding the interaction between the two class of drugs).

Single agent mTOR is much more risky and my reasons for believing SUCCEED might not "succeed".